The U.S. Food and Drug Administration (FDA) has not approved kratom or 7-OH for any purpose. These products cannot be legally marketed as treatments for any medical condition or as dietary supplements.
For centuries, people in Southeast Asia have used kratom in its original form for spiritual, religious, and medicinal purposes. The use of products sold as kratom and 7-OH has gained increased attention in recent years across the United States for recreational and medicinal purposes. Many people report that these products can support self treatment of anxiety and pain. Others claim they help manage opioid use disorders and addiction by relieving the effects of opioid withdrawal. More research is needed to understand how and why people use kratom and 7-OH products, as well as determine the extent to which these products are safe and effective for these purposes.
Although people report using kratom and products containing 7-OH for opioid use disorders, there are currently 3 FDA-approved medications to treat opioid use disorder in the United States. These are methadone, buprenorphine (e.g., Suboxone), and naltrexone (e.g., Vivitrol). These medications reduce opioid cravings, withdrawal symptoms, and overdose risk. However, there are many barriers to accessing these medications, preventing people from benefiting from the “gold standard” of treating opioid use disorder.
La mayoría de los estadounidenses apoyan un enfoque sanitario respecto a las drogas: centrarse en reducir el riesgo de consumo y sobredosis de drogas y priorizar los servicios de salud que ayudan a las personas a recuperarse, mantenerse seguras y prosperar.
Acción La crisis de sobredosis es una emergencia de salud pública. La Drug Policy Alliance aboga por un enfoque de salud pública en materia de drogas que pueda prevenir muertes por sobredosis y salvar vidas.
El tratamiento de la adicción puede ser un apoyo transformador para quienes la atraviesan. Infórmese sobre los modelos de tratamiento actuales, qué funciona y qué necesita mejorar.
